Another achievement to bring Radiotheranostics forward
300 hospitals registered on the Oncidium foundation Map! Another achievement [...]
NET Patient Testimonial, how PRRT saved Tom’s life
Tom is a composer, pianist, audio producer and neuroendocrine tumor patient. [...]
Diagnostic accuracy of F-18-PSMA-1007-PET/CT imaging for prostate carcinoma
J. Nucl. Me. 2020 Aug 17 18F-PSMA-1007-PET/CT reliably detects malignant [...]
IPET 2020 – all you need to know about Theranostics
Event: IPET 2020, Beyond the visible - International Conference on [...]
Radiopharmaceuticals Emerging as New Cancer Therapy
National cancer Institute. October 26, 2020 The last years have [...]
EANM ’20 – Let’s talk Radiotheranostics!
Event: EANM 2020 Annual Meeting - Virtual Edition Date: 22-30 [...]
Cu-64-Diasparagine (CuASP)
64Cu-Diasparagine (64CuASP) is a 64Cu-labeled peptide developed for the imaging [...]
Cu-67-SARTATE
67Cu-SARTATE (67Cu-SAR-[Tyr3]-Octreotate) is a therapeutic radiolabeled somatostatin analogue of [...]
Lu-177-PSMA-R2
177Lu-PSMA-R2 was developed as patent protected equivalent of 177Lu-PSMA-617. This [...]
Lu-177-EB-PSMA-617
177Lu-EB-PSMA-617 is a PSMA-617 analogue developed in China as an [...]